o_19ntugujs11ikbdrctt1teabbla.pdf

More documents

Recommendations

Info

3.5 Pegylated Liposomal Doxorubicin 3.6 Yondelis 3.7 Avastin 4 Product Pipeline 4.1 Overview of Pipeline by Phase and Route of Administration 4.2 Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target 4.2.1 Molecular Targets in the Developmental Pipeline 4.3 Clinical Trials 4.3.1 Clinical Trial Duration 4.3.2 Clinical Trial Size 4.3.3 Failure Rate 4.3.4 Discussion 4.4 Late-Stage Drugs in Developmental Pipeline 4.4.1 Niraparib 4.4.2 Olaparib 4.4.3 Vargatef 4.4.4 Trebananib 4.4.5 Farletuzumab 4.4.6 Karenitecin 4.5 Discussion 5 Market Forecasts 5.1 Asia-Pacific 5.1.1 Overview
5.1.2 Treatment Use Patterns and Revenues in Asia-Pacific Markets 5.2 India 5.2.1 Treatment Use Patterns 5.2.2 Annual Cost of Therapy 5.2.3 Market Forecast 5.3 China 5.3.1 Treatment Use Patterns 5.3.2 Annual Cost of Therapy 5.3.3 Market Forecast 5.4 Japan 5.4.1 Treatment Use Patterns 5.4.2 Annual Cost of Therapy 5.4.3 Market Forecast 5.5 Australia 5.5.1 Treatment Use Patterns 5.5.2 Annual Cost of Therapy 5.5.3 Market Forecast 5.6 Drivers and Barriers 5.6.1 Drivers 5.6.2 Barriers 6 Deals 6.1 Licensing Deals 6.1.1 Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338
Page 1 and 2: Ovarian Cancer Therapeutics in Asia
Page 3: 2 Introduction 2.1 Disease Pathophy
Page 7 and 8: 7.1.6 Phase III 7.1.7 Pre-Registrat
Page 9: Market Research Reports Search Engi

o_19ntugujs11ikbdrctt1teabbla.pdf

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?